Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

B-cell maturation antigen (BCMA)-directed bispecific antibodies have tolerable safety profiles in frail patients with relapsed/refractory multiple myeloma (MM), according to a real-world study ...

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

The researchers also observed significant increases in mortality for at least 1 age group for the following cancers: testicular cancer, uterine cancer, female breast cancer, bone and joint cancer, ...

The president has signed an executive order stating that the US will institute a “most-favored-nation” policy, whereby the US will pay the same price for a drug as the nation that pays the lowest ...

New research suggests that outpatients with cancer are more likely than other outpatients to have antimicrobial-resistant bacterial pathogens.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

President Donald Trump’s proposed budget for fiscal year 2026 would reduce the NIH budget by nearly $18 billion.

Experts say the Trump administration's cancellation of more than $800 million in research focused on LGBTQ patients could harm public health.

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

The risk of death from kidney cancer has decreased in the United States in recent years, but the risk varies by sex, race, and ethnicity, according to research published in The Oncologist.

Despite a congressional mandate to expand care for veterans, internal Veterans Affairs messages obtained by ProPublica paint a stark portrait of how chaotic cost cutting has already imperiled tests of ...